| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7638552 | MERZ PHARMS | Method for increasing the bioavailability of glycopyrrolate |
Aug, 2023
(7 months ago) | |
| US7816396 | MERZ PHARMS | Method for increasing the bioavailability of glycopyrrolate |
Aug, 2023
(7 months ago) | |
Cuvposa is owned by Merz Pharms.
Cuvposa contains Glycopyrrolate.
Cuvposa has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Cuvposa are:
- US7638552
- US7816396
Cuvposa was authorised for market use on 28 July, 2010.
Cuvposa is available in solution;oral dosage forms.
Cuvposa can be used as reduce chronic severe drooling (i.e., sialorrhea) in patients with neurologic conditions associated with problem drooling.
The generics of Cuvposa are possible to be released after 20 August, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 28, 2017 |
| New Product(NP) | Jul 28, 2013 |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 28 July, 2010
Treatment: Reduce chronic severe drooling (i.e., sialorrhea) in patients with neurologic conditions associated with problem drooling
Dosage: SOLUTION;ORAL
CUVPOSA family patents
